Will Oracle Go Bust?
After surging earlier this year, shares of cloud computing giant…
Sell
25
UPC Quote, Financials, Valuation and Earnings
Last price:
$3.58
Seasonality move
:
9.29%
Day range:
$3.54 - $3.81
52-week range:
$2.51 - $197.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.03x
P/B ratio:
0.04x
Volume:
5.8K
Avg. volume:
841.6K
1-year change:
-95.68%
Market cap:
$2.1M
Revenue:
$23M
EPS (TTM):
-$76.35
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Universe Pharmaceuticals, Inc. has -- downside to fair value with a price target of -- per share.
UPC vs. S&P 500
-
Over the past 5 trading days, Universe Pharmaceuticals, Inc. has underperformed the S&P 500 by -3.26% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Universe Pharmaceuticals, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Universe Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Universe Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Universe Pharmaceuticals, Inc. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Universe Pharmaceuticals, Inc. reported earnings per share of --.
Enterprise value:
-37.5M
EV / Invested capital:
--
Price / LTM sales:
0.03x
EV / EBIT:
--
EV / Revenue:
-1.94x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
7.59x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$7.6M
Return On Assets:
-32.15%
Net Income Margin (TTM):
-69.41%
Return On Equity:
-49.07%
Return On Invested Capital:
-42.98%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-11-18 | 2024-11-18 | 2024-11-18 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $61.8M | $51.7M | $52.5M | $33.5M | $65M | |
| Total Assets | $67.3M | $71.4M | $70.4M | $49.4M | $80.7M | |
| Current Liabilities | $16.6M | $10.2M | $23.2M | $20.6M | $23.4M | |
| Total Liabilities | $16.6M | $10.2M | $23.2M | $22.7M | $25.5M | |
| Total Equity | $50.7M | $61.2M | $47.1M | $26.7M | $55.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-11-18 | 2024-11-18 | 2024-11-18 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
UPC
Sector
Market Cap
$2.1M
$28.5M
Price % of 52-Week High
1.85%
50%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.05%
1-Year Price Total Return
-96.25%
-22.53%
Beta (5-Year)
--
0.573
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.72
200-day SMA
Sell
Level
$4.56
Bollinger Bands (100)
Sell
Level
3.27 - 5.09
Chaikin Money Flow
Sell
Level
-6.8M
20-day SMA
Sell
Level
$4.37
Relative Strength Index (RSI14)
Sell
Level
37.98
ADX Line
Sell
Level
24.17
Williams %R
Buy
Level
-94.5997
50-day SMA
Sell
Level
$4.71
MACD (12, 26)
Sell
Level
-0.38
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
52.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.4471)
Buy
CA Score
(Annual)
Level (-0.1799)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (0.9812)
Sell
Piotroski F Score
(Annual)
Level (2)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.
Stock Forecast FAQ
In the current month, UPC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UPC average analyst price target in the past 3 months is --.
-
Where Will Universe Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Universe Pharmaceuticals, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Universe Pharmaceuticals, Inc.?
Analysts are divided on their view about Universe Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Universe Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Universe Pharmaceuticals, Inc.'s Price Target?
The price target for Universe Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is UPC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Universe Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of UPC?
You can purchase shares of Universe Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Universe Pharmaceuticals, Inc. shares.
-
What Is The Universe Pharmaceuticals, Inc. Share Price Today?
Universe Pharmaceuticals, Inc. was last trading at $3.58 per share. This represents the most recent stock quote for Universe Pharmaceuticals, Inc.. Yesterday, Universe Pharmaceuticals, Inc. closed at $3.65 per share.
-
How To Buy Universe Pharmaceuticals, Inc. Stock Online?
In order to purchase Universe Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get UPC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
UPC
Sector
P/E ratio
--
23.23x
PEG ratio
0.00x
-0.01x
P/B ratio
0.04x
1.81x
Price / LTM sales
0.03x
1.57x
Growth Metrics
UPC
Sector
Revenue growth
--
4.8%
Earnings growth
--
9.72%
Revenue (5-year growth)
-7.08%
6.45%
Earnings forecast
--
-$0.20
Profitability
UPC
Sector
Profitability FY 2024
$5.8M
$3.7M
Return on invested capital
-42.98%
-30.68%
Return on assets
-32.15%
-27.59%
Return on equity
-49.07%
-36.13%
Earnings Date
Last Earnings Date
Nov
18
Next Earnings Date
Nov
18
Estimated Next Earnings Date
Feb
17
Balance Sheet
UPC
Sector
Total cash
$11.4M
$28.1M
Short term investments
$13.2M
$26M
Total assets
$68M
$80.3M
Long term debt
$6.5M
$5.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Nebius Stock Up?
Nebius (NASDAQ:NBIS) is an AI infrastructure business that operates large…
Will Robinhood Win Tokenization?
For many years, cryptocurrency enthusiasts have predicted a mass tokenization…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 37x
Alerts
Buy
59
SRRK alert for Nov 18
Scholar Rock Holding Corp. [SRRK] is down 2.59% over the past day.
Buy
84
ZCSH alert for Nov 18
Grayscale Zcash Trust (ZEC) [ZCSH] is up 1.02% over the past day.
Buy
78
JAZZ alert for Nov 18
Jazz Pharmaceuticals Plc [JAZZ] is up 20.59% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
